Foothills Medical Centre
Calgary, Alberta, T2N 2T9, Canada
NCT Number: NCT07697742
ELIMINATE is a cohort study, phase 2A, designed to determine whether a standardized microsurgical procedure to evacuate spontaneous lobar intracranial hemorrhage (ICH) is feasible, safe and surgically efficacious in achieving a postoperative residual ICH volume <15cc on 24-hour postoperative CT imaging.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Calgary, Alberta, T2N 2T9, Canada
The primary objective of ELIMINATE, a prospective, single-centre, observational surgical cohort study, is to determine whether a standardized microsurgical procedure to evacuate spontaneous lobar intracranial hemorrhage (ICH) is feasible, safe and surgically efficacious in achieving a postoperative residual ICH volume <15cc on 24-hour postoperative CT imaging. The secondary objectives include assessment of tool-tissue forces and bleeding, residual ICH volume postoperatively, and determining the recruitment rate for patients with spontaneous lobar ICH.
The primary clinical outcome will be the proportion of enrolled patients achieving residual ICH volume <15cc on postoperative CT scan at 24 hours. Key outcomes are:
Radiographic: percent evacuation; residual volume (continuous + dichotomized). Functional: mRS at 6 months; EQ-5D-5L at 6 months; mortality at 30 and 180 days.
Intraoperative: force metrics; bleeding quantification; operative time; blood loss.
Feasibility: recruitment rate; proportion operated ≤16 hours; completeness of imaging.
Safety: symptomatic rebleeding ≤72h; postoperative deficits; infections; unplanned OR return; 30-day mortality.
A maximum of 27 adult patients will be enrolled.
Inclusion criteria
Exclusion criteria
This study consists of one 180-day study period for each subject. Subjects will be hospitalized for care after their lobar ICH and surgical intervention according to the current standard of care. Subjects will undergo phone assessment on Day 180 by a trained assessor.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Microsurgical hematoma evacuation using microscope and neuronavigation
Time frame: Quarterly from study onset through study completion with the final recruitment rate recorded at the end of study; total time 12 months
Total recruitment will be recorded each month and report as number of patients recruited per calendar month as an average for duration of the study. The numerator will be the cumulative total number of pateints recruitment and the denominator will be the number of months elapsed since study start. The demoninator can be a fractional number; the numerator will also be a positive integer.
Time frame: Up to 2 days after enrolment; post-operative core lab assessment of the 18-54 hour follow-up CT brain scan. The Core Lab will measure residual hematoma volume using summative planimetry over the volume of each CT scan slice image.
Residual hematoma volume
Time frame: at 90 days and 180 days after enrolment.
mRS score is an integer scale ranging from 0 to 6 (7 point interval scale). Lower score are better and the highest score (6) implies death
Time frame: at 90 days and 180 days after randomization
EQ5D-5L is a 5 domain scale, with a 5 point Likert scale for the quesiton in each domain. It addresses quality of life and the final score (the EQ5D Index) is adjusted by country to local norms using standardized methodology. Higher index scores inply a higher quality of life.
Time frame: Perioperative/peri-procedural
Intra-operative forceps forces during microsurgery. These devices have haptic measurement capability and will reocrd the degree of force each time dissection or cautery are used. Recording will be conducted during the entire operative procedure.
Contact information is provided by the study sponsor or research team.
Dr. Michael D Hill
Other
Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE): A Prospective Observational Surgical Cohort Study of Feasibility, Safety, and Radiographic Outcomes
Acronym: ELIMINATE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07026994
Amyloidosis, Brain Diseases
Beijing, China
View Trial DetailsNCT07471256
Intracerebral Hemorrhage Lobar
Beijing, China
View Trial DetailsNCT06921616
Brain Diseases, Cardiovascular Diseases
Luzhou, China
View Trial DetailsNCT07736820
Brain Damage, Chronic, Brain Diseases
Nicosia, Cyprus
View Trial Details